Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol

GALECTIN THERAPEUTICS INC

Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.
Cash $15.1M at Dec 31, 2024; new $5M line of credit from chairman in March 2025; cash runway through Aug 2025.
NAVIGATE trial: varices incidence reduced 49.3% (p=0.04) in per-protocol for belapectin 2 mg vs placebo.
In US per-protocol patients, varices reduced 68.1% (p=0.02); ITT population did not reach significance.
Additional biomarker data expected Q2 2025; belapectin has FDA Fast Track Designation for MASH cirrhosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.